RESUMO
Objective:To explore the level changes and clinical significance of peripheral blood fibrinogen (FIB) and its degradation products (FDP) in patients with multiple myeloma (MM).Methods:One hundred and two MM patients who treated in Tongling People's Hospital from January 2015 to April 2018 were selected and divided into good prognosis group and poor prognosis group according to the prognosis. The correlation between the levels of FIB and FDP in peripheral blood and prognosis and the predictive value of poor prognosis were analyzed, and the survival was analyzed.Results:The ratio of tumor cells in bone marrow, international staging system (ISS) stage, and the levels of serum hemoglobin, albumin, creatinine, and β2-microglobulin in good prognosis group and poor prognosis group had significant differences ( P<0.05). The levels of peripheral blood FIB and FDP in the poor prognosis group and after 3 cycles of chemotherapy were higher than those in the good prognosis group: before chemotherapy: (4.71 ± 0.68) g/L vs. (4.02 ± 0.65) g/L, (50.56 ± 9.14) mg/L vs. (37.52 ± 8.25) mg/L; after 3 cycles of chemotherapy: (4.15 ± 0.62) g/L vs. (3.42 ± 0.53) g/L, (42.28 ± 9.51) mg/L vs. (6.59 ± 1.60) mg/L, there were statistical differences ( P<0.05). Controlled other factors after chemotherapy, the peripheral blood FIB and FDP of 1 cycle, 3 cycles of chemotherapy were still significantly related to the prognosis ( P<0.05). The area under the curve value of the combination of peripheral blood FIB and FDP before chemotherapy was 0.852, which was greater than independent detection of any index. The 2-year survival rate of patients with high levels of FIB and FDP were lower than those of patients with low levels ( P<0.05). Conclusions:Peripheral blood FIB and FDP of MM patients are independent risk factors that affect the prognosis. An increase in their levels indicates a poor prognosis. Clinical treatment can be actively improved according to the changes in the levels of the two to ensure the maximum benefit for patients.